For example, in first line advanced NSCLC, both monotherapy pembrolizumab and pembrolizumab + chemotherapy are approved for patients with PD-L1 IHC (TPS) ≥ 1% and ≥50%, however prospective data is not available to guide monotherapy vs. combination therapy decision making. Here, CD274 is linked to non-small cell lung carcinoma.